IP Library Granted Patent US 10,375,938
Granted Patent B2
US 10,375,938 · App. 15/888,581 · Granted Aug 13, 2019

Multiplexed genome editing

Inventors: George M. Church (Brookline, MA); Luhan Yang (Somerville, MA); Marc Guell (Barcelona, ES)
Assignee: President and Fellows of Harvard College
A01K67/0275A01K67/0273C12N7/00C12N9/22C12N15/11C12N15/1132C12N15/63C12N15/907A01K2227/108C12N2310/20C12N2740/10062C12N2800/80
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,375,938
App. No.
15/888,581
Granted
Aug 13, 2019
Kind
B2
Abstract

A method of modulating some or all copies of a gene in a cell is provided including introducing into a cell one or more ribonucleic acid (RNA) sequences that comprise a portion that is complementary to all or a portion of each of the one or more target nucleic acid sequences, and a nucleic acid sequence that encodes a Cas protein and maintaining the cells under conditions in which the Cas protein is expressed and the Cas protein binds and modulates the one or more target nucleic acid sequences in the cell.

Claims (22)

1. A method of altering porcine endogenous retrovirus (PERV) pol genes in a cell comprising:

introducing into the cell a Cas protein and guide RNAs, wherein each guide RNA comprises a sequence that is complementary to a portion of a PERV pol gene; and

maintaining the cell under conditions in which the guide RNAs and the Cas protein form co-localization complexes with a plurality of PERV pol genes and the Cas protein cuts at least 20% of the PERV pol genes.

2. The method of claim 1 , wherein the cuts to the PERV pol genes result in

indels or mutations.

3. The method of claim 1 , wherein the cell is a mammalian cell.

4. The method of claim 1 , wherein the cell is from an embryo.

5. The method of claim 1 , wherein the cell is a stem cell, zygote, or a germ line cell.

6. The method of claim 1 , wherein the cell is an embryonic stem cell or pluripotent stem cell.

7. The method of claim 1 , wherein the cell is a somatic cell.

8. The method of claim 1 , wherein the cell is a eukaryotic cell.

9. The method of claim 1 , wherein the cell is an animal cell.

10. The method of claim 1 , wherein the cell is a porcine cell.

11. The method of claim 1 , wherein all copies of the PERV pol genes are cut.

12. The method of claim 1 , wherein at least 97% of the PERV pol genes are cut.

13. The method of claim 12 , wherein the cuts to the pol genes result in indels or mutations.

14. The method of claim 13 , wherein the cell has at least a 1000-fold reduction in PERV transmission to a second cell compared to a wild type control cell.

15. The method of claim 14 , wherein the second cell is a human cell.

16. The method of claim 1 , wherein the cuts present in at least 20% of PERV pol genes are determined by sequencing.

17. The method of claim 1 , wherein the cell contains intact PERV gag and/or env genes.

18. The method of claim 1 , wherein at least 50% of the PERV pol genes comprise genomic indels.

19. The method of claim 1 , wherein at least 80% of the PERV pol genes comprise genomic indels.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2018
From: CHURCH, GEORGE M.; GUELL, MARC; YANG, LUHAN
To: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Reel/Frame 047764/0097 →
CONFIRMATORY LICENSE Recorded Jul 16, 2018
From: HARVARD UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 046545/0450 →
Continuity (3)
Continuation PCTUS2016055916 · Oct 7, 2016
Provisional Application 62239239 · Oct 8, 2015
Related Publication 20180171361A1 · Jun 21, 2018
Cited By (4)
US 12,612,643 US 12,630,838 US 12,637,690 US 12,649,928